Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedThe study record now shows that results have been posted for OP-1250, replacing prior results-submission statuses, and includes detailed study design, eligibility criteria, cohorts, outcomes, and links to associated documents.SummaryDifference3%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page footer now shows a newer ClinicalTrials.gov release revision identifier (“v3.5.3” instead of “v3.5.2”). This reflects a site/version update rather than a substantive change to the study details.SummaryDifference0.1%

- Check30 days agoChange DetectedFooter revision label changed from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check59 days agoChange DetectedFooter revision label updated from v3.4.3 to v3.5.0. No study details or user-facing content are affected.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check95 days agoChange DetectedThe update adds Revision: v3.4.2 and removes the prior government funding/operating status notices; overall study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.